What CMS stood up
The Medicare GLP-1 Bridge is a time-limited demonstration. Dates: 1 July 2026 through 31 December 2027. Patient pay: $50 per month. Products: Wegovy injection, Wegovy pill, Foundayo, Zepbound KwikPen.
It is not a finding that obesity drugs are now standard Part D. It is not plan enrollment. VitalHound is not affiliated with CMS and does not determine eligibility.
Who the processor will look at
Part D or MA-PD. Generally no GLP-1 already filled through Part D in 2026. A BMI tier that matches published screens. A prescriber-submitted PA. A listed product-device pair.
Indications CMS treats as ordinary Part D — type 2 diabetes, moderate-to-severe OSA, MASH — stay off this path.
What the $50 is not
Not deductible credit. Not TrOOP. Not Extra Help. Not a commercial savings card. Not a 2028 benefit.
If the demonstration is the wrong or closed path
Part D for covered indications. Manufacturer cash (often $149–$299). Commercial-plus-card ~$25 only for commercial members. Telehealth ~$449 is usually the expensive panic buy.
Where to verify
Medicare.gov/glp1bridge and the current CMS FAQs. This site is educational software dated 19 August 2026.
Questions
Can I apply by myself?
Does every Medicare Advantage plan 'have Bridge'?
Is $50 guaranteed if my BMI is high?
When does it end?
Not sure this applies to you?
Answer a few questions and see your own numbers.
Free to see which path is likely cheapest for your coverage.
Check my options